Modification of MyD88 splicing using modified oligonucleotides

Details Modification of MyD88 splicing using modified oligonucleotides Modification of MyD88 splicing using modified oligonucleotides

2011-02-01

2011-02-01

Whiteman, Brian (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

07879992

ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.

REFERENCES:
patent: 5627274 (1997-05-01), Kole et al.
patent: 5665593 (1997-09-01), Kole et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5916808 (1999-06-01), Kole et al.
patent: 5976879 (1999-11-01), Kole et al.
patent: 6183966 (2001-02-01), Gray et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 7033830 (2006-04-01), Karras et al.
patent: 2002/0049173 (2002-04-01), Bennett et al.
patent: 2003/0186903 (2003-10-01), Karras et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2004/0038926 (2004-02-01), Karras et al.
patent: 2005/0059071 (2005-03-01), Eriksson et al.
patent: 2005/0181476 (2005-08-01), Beyaert et al.
patent: 2006/0211642 (2006-09-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0031850 (2007-02-01), Mounts et al.
patent: WO 94/26887 (1994-11-01), None
patent: WO 02/38738 (2002-05-01), None
patent: WO 03046132 (2003-06-01), None
Tuschl et al. (The siRNA user guide, 2001).
Adachi, O. et al., “Targeted Disruption of theMyD88Gene Results in Loss of IL-I- and IL-18-Mediated Function,”Immunity(1998) 9:143-150.
Björkbacka, H. et al., “Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways,”Nature Med. (2004) 10(4):416-421.
Burns, K. et al., “MyD88, an Adapter Protein Involved in Interleukin-1 Signaling,”J. Biol. Chem. (1998) 273(20):12203-12209.
Burns, K. et al., “Inhibition of Interleukin I Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4,”J. Exp. Med. (2003) 197(2):263-268.
Cao, Z. et al., “TRAF6 is a signal transducer for interleukin-1”,Nature(1996) 383:443-444.
Cartegni, L. et al., “Correction of disease-associated exon skipping by synthetic exon-specific activators,”Nature Structural Biol. (2003) 10(2):120-125.
Garcia-Blanco, M. A. et al., “Alternative splicing in disease and therapy,”Nature Biotech. (2004) 22(5):535-546.
Harborth, J. et al., “Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing,”Antisense Nucl. Acid Drug Dev. (2003) 13:83-105.
Hardiman, G. et al., “Genetic Structure and Chromosomal Mapping of MyD88,”Genomics(1997) 45:332-339.
Jenssens, S. et al., “Regulation of Interleukin-l—and Lipopolysaccharide-Induced NF-κB Activation by Alternative Splicing of MyD88,”Curr. Biol. (2002) 12:467-471.
Karras, J. G. et al., “Deletion of Individual Exons and Induction of Soluble Murine Interleukin-5 Receptor-α Chain Expression through Antisense Oligonucleotide-Mediated Redirection of Pre-mRNA Splicing,”Mol. Pharmacol. (2000) 58:380-387.
Kawai, T. et al., “Unresponsiveness of MyD88-Deficient Mice to Endotoxin,”Immunity(1999) 11:115-122.
Medzhitov, R. et al., “MyD88 Is an Adaptor Protein in the hToll/IL-1 Receptor Family Signaling Pathways,”Mol. Cell(1998) 2:253-258.
Sazani, P. et al., “Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing,”J. Clin. Invest.(2003) 112(4):481-486.
Scaffidi, P. et al., “Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome,”Nature Med. (2005) 11(4):440-445.
Taylor, J. K. et al., “Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides,”Nature Biotech. (1999) 17:1097-1100.
Schnare, M. et al., “Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88,”Curr. Biol. (2000) 10:1139-1142.
Weighardt, H. et al., “Cutting Edge: Myeloid Differentiation Factor 88 Deficiency Improves Resistance Against Sepsis Caused by Polymicrobial Infection,”J. Immunol. (2002) 169:2823-2827.
Wesche, H. et al., “MyD88: An Adapter That Recruits IRAK to the IL-1 Receptor Complex,”Immunity(1997) 7:837-847.
Yamamoto, M. et al., “Essential role for TIRAP in activation of the signaling cascade shared by TLR2 and TLR4,”Nature(2002) 420:324-329.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.

Affiliated with

Also associated with

Rating

Modification of MyD88 splicing using modified oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modification of MyD88 splicing using modified oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modification of MyD88 splicing using modified oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2623714